{"id":"cggv:4a150cd9-e16b-4992-8cc7-5ccec44b4d6bv1.1","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:4a150cd9-e16b-4992-8cc7-5ccec44b4d6b_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10025","date":"2018-09-25T16:00:00.000Z","role":"Approver"},{"id":"cggv:4a150cd9-e16b-4992-8cc7-5ccec44b4d6b_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10025","date":"2021-01-08T19:22:15.760Z","role":"Publisher"}],"evidence":[{"id":"cggv:4a150cd9-e16b-4992-8cc7-5ccec44b4d6b_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:4a150cd9-e16b-4992-8cc7-5ccec44b4d6b_cc_el","type":"EvidenceLine","evidence":[{"id":"cggv:f2717eae-a8bb-416f-b398-f8374e58e805","type":"EvidenceLine","evidence":[{"id":"cggv:f2717eae-a8bb-416f-b398-f8374e58e805_cc_evidence_item","type":"Finding","caseCohort":{"id":"cggv:d4cfa8c3-279f-40da-b645-a874582e997a","type":"Cohort","allGenotypedSequenced":38,"alleleFrequency":0.131578947368421,"detectionMethod":"Only CALM genes were analyzed","evidence":[{"id":"cggv:f2717eae-a8bb-416f-b398-f8374e58e805_cc_evidence_item"}],"numWithVariant":5,"relatedCondition":{"id":"obo:MONDO_0002442"}},"controlCohort":{"id":"cggv:46275bf7-2f66-46a8-97b4-653e365dd962","type":"Cohort","allGenotypedSequenced":60706,"alleleFrequency":0.0003788752347379172,"evidence":[{"id":"cggv:f2717eae-a8bb-416f-b398-f8374e58e805_cc_evidence_item"}],"numWithVariant":23},"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.00010,"statisticalSignificanceType":"Chi-Sq","statisticalSignificanceValueType":"Other","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26969752","type":"dc:BibliographicResource","dc:abstract":"Calmodulin (CaM) is encoded by 3 genes, CALM1, CALM2, and CALM3, all of which harbor pathogenic variants linked to long QT syndrome (LQTS) with early and severe expressivity. These LQTS-causative variants reduce CaM affinity to Ca(2+) and alter the properties of the cardiac L-type calcium channel (CaV1.2). CaM also modulates NaV1.5 and the ryanodine receptor, RyR2. All these interactions may play a role in disease pathogenesis. Here, we determine the spectrum and prevalence of pathogenic CaM variants in a cohort of genetically elusive LQTS, and functionally characterize the novel variants.","dc:creator":"Boczek NJ","dc:date":"2016","dc:title":"Spectrum and Prevalence of CALM1-, CALM2-, and CALM3-Encoded Calmodulin Variants in Long QT Syndrome and Functional Characterization of a Novel Long QT Syndrome-Associated Calmodulin Missense Variant, E141G."},"rdfs:label":"01"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":2},{"id":"cggv:4a150cd9-e16b-4992-8cc7-5ccec44b4d6b_ad_other_el","type":"EvidenceLine","evidence":[{"id":"cggv:c4922a31-ee1b-4fbe-aa15-bbc86f86b88c_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:69ae0b85-99a4-4f25-85aa-1c1353ad9978","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"ethnicity":{"id":"cg:NotHispanicOrLatino"},"previousTesting":true,"previousTestingDescription":"Negative clinical testing (KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2)","sex":"Male","variant":{"id":"cggv:c4922a31-ee1b-4fbe-aa15-bbc86f86b88c_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:2e5e68d5-8ecc-44ea-a80a-a37a92c56d32","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006888.6(CALM1):c.426C>G (p.Phe142Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA186015"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23388215","type":"dc:BibliographicResource","dc:abstract":"Life-threatening disorders of heart rhythm may arise during infancy and can result in the sudden and tragic death of a child. We performed exome sequencing on 2 unrelated infants presenting with recurrent cardiac arrest to discover a genetic cause.","dc:creator":"Crotti L","dc:date":"2013","dc:title":"Calmodulin mutations associated with recurrent cardiac arrest in infants."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23388215","rdfs:label":"04"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"cggv:93c463fd-d7da-4878-a260-5ed4219181f3_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:ff6195a8-7c3b-4d33-858f-8218731fb526","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":16,"detectionMethod":"Variants found by whole-exome sequencing (performed in two family members) were validated and tested for segregation in the family by Sanger sequencing.  A total of 500 control individuals of Moroccan descent were tested for the presence of the CALM1 p.F90L variant by Sanger sequencing.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Mild QTc prolongation in the recovery phase after exercise and idiopathic ventricular fibrillation before the age of 17 years.","phenotypes":"obo:HP_0001663","previousTesting":true,"previousTestingDescription":"Candidate gene analysis was carried out in DPP6, KCNQ1,KCNH2, SCN5A,KCNE1,KCNE2, RYR2, CASQ2, KCNJ2, TMEM43, JUP, DSG2, TNNT2, and PKP2. These genes were polymerase chain reaction-amplified, and the purified polymerase chain reaction products were Sanger sequenced.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:93c463fd-d7da-4878-a260-5ed4219181f3_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:f78f7c94-6639-4092-8187-ebddfaf8083b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006888.6(CALM1):c.268T>C (p.Phe90Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA186017"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24076290","type":"dc:BibliographicResource","dc:abstract":"This study aimed to identify the genetic defect in a family with idiopathic ventricular fibrillation (IVF) manifesting in childhood and adolescence.","dc:creator":"Marsman RF","dc:date":"2014","dc:title":"A mutation in CALM1 encoding calmodulin in familial idiopathic ventricular fibrillation in childhood and adolescence."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24076290","rdfs:label":"Proband 1"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"cggv:00931529-419b-4934-a639-bc3ef24896d2_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:9d6a00d8-18b2-4665-91e8-4f7ec97b0b9b","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":1,"ethnicity":{"id":"cg:NotHispanicOrLatino"},"previousTesting":true,"previousTestingDescription":"Negative clinical genetic testing (KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2)","sex":"Male","variant":{"id":"cggv:00931529-419b-4934-a639-bc3ef24896d2_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:b4af1dd5-1f88-46be-9b99-99e1717561b2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006888.6(CALM1):c.389A>G (p.Asp130Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA186013"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23388215"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23388215","rdfs:label":"03"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":1.5},{"id":"cggv:4a150cd9-e16b-4992-8cc7-5ccec44b4d6b_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"cggv:9090200f-b27d-464b-bc3d-94dbb981ead8_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:f26ad8d6-2232-4e62-aa66-d4beb17cabe5","type":"Proband","sex":"UnknownEthnicity","variant":{"id":"cggv:9090200f-b27d-464b-bc3d-94dbb981ead8_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:b4af1dd5-1f88-46be-9b99-99e1717561b2"},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31170290","type":"dc:BibliographicResource","dc:abstract":"Calmodulinopathies are rare life-threatening arrhythmia syndromes which affect mostly young individuals and are, caused by mutations in any of the three genes (CALM 1-3) that encode identical calmodulin proteins. We established the International Calmodulinopathy Registry (ICalmR) to understand the natural history, clinical features, and response to therapy of patients with a CALM-mediated arrhythmia syndrome.","dc:creator":"Crotti L","dc:date":"2019","dc:title":"Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290","rdfs:label":"4"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:796e2d4a-3600-468c-9cee-2651a8db83e6_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:238a08f5-6aec-486a-9505-cfabe891ba45","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":3,"firstTestingMethod":"Exome sequencing","sex":"Male","variant":{"id":"cggv:796e2d4a-3600-468c-9cee-2651a8db83e6_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:93dd1a5f-0521-48d0-b3c9-e64ee9cee7ee","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005184.4(CALM3):c.396T>A (p.Asp132Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/423164"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/27374306","type":"dc:BibliographicResource","dc:abstract":"Calmodulin (CaM) mutations are associated with cardiac arrhythmia susceptibility including congenital long QT syndrome (LQTS).","dc:creator":"Pipilas DC","dc:date":"2016","dc:title":"Novel calmodulin mutations associated with congenital long QT syndrome affect calcium current in human cardiomyocytes."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27374306","rdfs:label":"02"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:361e4ff4-4a55-4acb-b493-718d8fdfd65d_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:dbd0fcc5-add6-4203-bc7e-4e60ed1f20bf","type":"Proband","sex":"UnknownEthnicity","variant":{"id":"cggv:361e4ff4-4a55-4acb-b493-718d8fdfd65d_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:b4af1dd5-1f88-46be-9b99-99e1717561b2"},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290","rdfs:label":"2"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:dea6a594-8430-4141-8be6-23f628d3681c_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:3d4ea132-67ce-4b2e-bfa0-722b3b4ee1f1","type":"Proband","sex":"UnknownEthnicity","variant":{"id":"cggv:dea6a594-8430-4141-8be6-23f628d3681c_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:af0498a4-65c8-4b2c-bd57-159fb138365b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006888.6(CALM1):c.424T>C (p.Phe142Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA390690445"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290","rdfs:label":"3"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:2248b837-320d-4688-9237-f47999e08265_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:f37a247d-59e2-4656-b516-fa910a53b1a6","type":"Proband","sex":"UnknownEthnicity","variant":{"id":"cggv:2248b837-320d-4688-9237-f47999e08265_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:00c7d409-71fe-45a9-ad6a-5729ebe2b75e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006888.6(CALM1):c.293A>G (p.Asn98Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343812"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31170290","rdfs:label":"1"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:c3f295b7-f8f4-4a6d-96a1-c828ca7feb0b_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:d404afba-2b76-4bf1-bfe8-2e4a1813dd43","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"Clinical genetic testing (KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2) negative","sex":"Female","variant":{"id":"cggv:c3f295b7-f8f4-4a6d-96a1-c828ca7feb0b_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:b4af1dd5-1f88-46be-9b99-99e1717561b2"},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23388215"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23388215","rdfs:label":"01"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":12}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:4a150cd9-e16b-4992-8cc7-5ccec44b4d6b_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:4a150cd9-e16b-4992-8cc7-5ccec44b4d6b_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:3bc92f9a-dbd1-4d40-b9cd-3cc511e5679b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c3d3c0c1-fb16-4dc7-872b-dff30023a9cc","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"RT-PCR from control samples (origin not detailed)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23388215","rdfs:label":"RT-PCR"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"cggv:6a704067-b71e-4a18-81db-be417130dcb1","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:523dcd09-4a71-4465-9d6b-908b14520258","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"Robust evidence associating KCNQ1 with LQTS","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/16556865","type":"dc:BibliographicResource","dc:abstract":"The slow IKS K+ channel plays a major role in repolarizing the cardiac action potential and consists of the assembly of KCNQ1 and KCNE1 subunits. Mutations in either KCNQ1 or KCNE1 genes produce the long-QT syndrome, a life-threatening ventricular arrhythmia. Here, we show that long-QT mutations located in the KCNQ1 C terminus impair calmodulin (CaM) binding, which affects both channel gating and assembly. The mutations produce a voltage-dependent macroscopic inactivation and dramatically alter channel assembly. KCNE1 forms a ternary complex with wild-type KCNQ1 and Ca(2+)-CaM that prevents inactivation, facilitates channel assembly, and mediates a Ca(2+)-sensitive increase of IKS-current, with a considerable Ca(2+)-dependent left-shift of the voltage-dependence of activation. Coexpression of KCNQ1 or IKS channels with a Ca(2+)-insensitive CaM mutant markedly suppresses the currents and produces a right shift in the voltage-dependence of channel activation. KCNE1 association to KCNQ1 long-QT mutants significantly improves mutant channel expression and prevents macroscopic inactivation. However, the marked right shift in channel activation and the subsequent decrease in current amplitude cannot restore normal levels of IKS channel activity. Our data indicate that in healthy individuals, CaM binding to KCNQ1 is essential for correct channel folding and assembly and for conferring Ca(2+)-sensitive IKS-current stimulation, which increases the cardiac repolarization reserve and hence prevents the risk of ventricular arrhythmias.","dc:creator":"Shamgar L","dc:date":"2006","dc:title":"Calmodulin is essential for cardiac IKS channel gating and assembly: impaired function in long-QT mutations."},"rdfs:label":"Multiple"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"cggv:4a150cd9-e16b-4992-8cc7-5ccec44b4d6b_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:42e21bd3-0223-42c3-a8d1-eaa7499923bc","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0435a446-b006-487c-871a-d9688c79f7b6","type":"FunctionalAlteration","dc:description":"CALM1 mutations (D130G and F142L) caused both increased action potential duration (APD) and heightened Ca2+ transients. In addition, the mutations had the potential to strongly suppress Ca2+/CaM-dependent inactivation of the L-type calcium current.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24816216","type":"dc:BibliographicResource","dc:abstract":"Recent work has identified missense mutations in calmodulin (CaM) that are associated with severe early-onset long-QT syndrome (LQTS), leading to the proposition that altered CaM function may contribute to the molecular etiology of this subset of LQTS. To date, however, no experimental evidence has established these mutations as directly causative of LQTS substrates, nor have the molecular targets of CaM mutants been identified. Here, therefore, we test whether expression of CaM mutants in adult guinea-pig ventricular myocytes (aGPVM) induces action-potential prolongation, and whether affiliated alterations in the Ca(2+) regulation of L-type Ca(2+) channels (LTCC) might contribute to such prolongation. In particular, we first overexpressed CaM mutants in aGPVMs, and observed both increased action potential duration (APD) and heightened Ca(2+) transients. Next, we demonstrated that all LQTS CaM mutants have the potential to strongly suppress Ca(2+)/CaM-dependent inactivation (CDI) of LTCCs, whether channels were heterologously expressed in HEK293 cells, or present in native form within myocytes. This attenuation of CDI is predicted to promote action-potential prolongation and boost Ca(2+) influx. Finally, we demonstrated how a small fraction of LQTS CaM mutants (as in heterozygous patients) would nonetheless suffice to substantially diminish CDI, and derange electrical and Ca(2+) profiles. In all, these results highlight LTCCs as a molecular locus for understanding and treating CaM-related LQTS in this group of patients. ","dc:creator":"Limpitikul WB","dc:date":"2014","dc:title":"Calmodulin mutations associated with long QT syndrome prevent inactivation of cardiac L-type Ca(2+) currents and promote proarrhythmic behavior in ventricular myocytes."},"rdfs:label":"Electrophysiology studies of CALM1 mutations"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"cggv:1cc2f5c7-c3dc-41de-b4be-c60a9307c607","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:24d0041a-51f2-4328-bb31-2e1565b69f84","type":"FunctionalAlteration","dc:description":"Reduction in Ca-binding affinity","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26969752","rdfs:label":"Whole cell patch-clamp"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"cggv:804a770d-0f6e-4f41-b9cb-80a758d4c898","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0a0657f8-0704-40c4-8abf-959fdba0c3e4","type":"FunctionalAlteration","dc:description":"CALM1 mutants (D130G and F142L) impaired the  Ca2+-dependent inactivation of L-type Ca2+ current.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24958779","type":"dc:BibliographicResource","dc:abstract":"Calmodulin (CaM) mutations have been identified recently in subjects with congenital long QT syndrome (LQTS) or catecholaminergic polymorphic ventricular tachycardia (CPVT), but the mechanisms responsible for these divergent arrhythmia-susceptibility syndromes in this context are unknown. We tested the hypothesis that LQTS-associated CaM mutants disrupt Ca2+ homeostasis in developing cardiomyocytes possibly by affecting either late Na current or Ca2+-dependent inactivation of L-type Ca2+ current.","dc:creator":"Yin G","dc:date":"2014","dc:title":"Arrhythmogenic calmodulin mutations disrupt intracellular cardiomyocyte Ca2+ regulation by distinct mechanisms."},"rdfs:label":"Electrophysiology studies of CALM1 D130G & F142L mutation"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"cggv:22634cab-18e6-4e3d-af59-c02775109024","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0dc2f685-6f85-42eb-9cc2-d75932c25dfd","type":"FunctionalAlteration","dc:description":"Impaired Ca-dependent inactivation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27374306","rdfs:label":"Whole-cell patch clamp"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"cggv:11f3b57d-857b-4224-a315-b02e4ad447e7","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:e7393cec-4af2-4f29-a09e-02880d9605f1","type":"FunctionalAlteration","dc:description":"APD and QT prolongation","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28158429","type":"dc:BibliographicResource","dc:abstract":"Calmodulin (CaM) is a small protein, encoded by three genes (CALM1-3), exerting multiple Ca2+-dependent modulatory roles. A mutation (F142L) affecting only one of the six CALM alleles is associated with long QT syndrome (LQTS) characterized by recurrent cardiac arrests. This phenotypic severity is unexpected from the predicted allelic balance. In this work, the effects of heterozygous CALM1-F142L have been investigated in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) obtained from a LQTS patient carrying the F142L mutation, i.e. in the context of native allelic ratio and potential gene modifiers.","dc:creator":"Rocchetti M","dc:date":"2017","dc:title":"Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes."},"rdfs:label":"iPS/ patch clamp"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3}],"evidenceStrength":"Definitive","sequence":1783,"specifiedBy":"GeneValidityCriteria7","strengthScore":15,"subject":{"id":"cggv:d605af3f-3f42-4b28-84d1-e0ad144a45f9","type":"GeneValidityProposition","disease":"obo:MONDO_0002442","gene":"hgnc:1442","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","dc:description":"Calmodulin is a calcium-binding protein that is essential for multiple intracellular processes including modulation of cardiac ion channels. An exactly identical calmodulin protein is encoded by 3 separate genes, CALM1-3, located on different chromosomes (14, 2 and 19, respectively). \nIn 2013 Crotti et al. were the first to identify de-novo missense variants in CALM1 and CALM2 in 2 patients with a unique phenotype (PMID 23388215). Both were infants presenting with marked QT prolongation, life-threatening ventricular arrhythmias and intermittent AV block. Subsequent studies identified multiple similar cases with de-novo variants in one of the 3 CALM genes. Based on this evidence the Expert Panel classified all calmoudulin genes (CALM1-3) as having a 'Definitive' level of evidence for disease causation of LQTS with atypical features presenting in childhood. \nNote: All LQTS genes were curated by 3 separate blinded teams. The evidence and scores reached by these 3 teams were reviewed by the LQTS Clinical Domain Expert Panel. For a detailed discussion of this group's work and the separate scores of the 3 teams please see \"Adler et al. An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation 2020;141(6):418-428. doi: 10.1161/CIRCULATIONAHA.119.043132‚Äù\nAbundance of genetic data over time","dc:isVersionOf":{"id":"cggv:4a150cd9-e16b-4992-8cc7-5ccec44b4d6b"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}